Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dyne Therapeutics (DYN)
NASDAQ:DYN
Holding DYN?
Track your performance easily
DYN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.40 - $47.45
Previous Close$33.67
Volume682.44K
Average Volume (3M)1.27M
Market Cap
$3.38B
Enterprise Value$2.63B
Total Cash (Recent Filing)$778.84M
Total Debt (Recent Filing)$25.72M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Oct 31, 2024EPS Estimate
-$0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.58
Shares Outstanding100,400,798
10 Day Avg. Volume876,141
30 Day Avg. Volume1,271,662
Standard Deviation0.22
R-Squared0.05
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)4.36
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-15.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-9.81
Forecast
1Y Price Target
$52.50Price Target Upside55.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Dyne Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DataDYNE-251 demonstrates improvements in dystrophin expression (20mg/kg Q4W) that importantly translate into early functional benefits in DMD.
Financial PerformanceThe company ended the quarter with cash, equivalents, and marketable securities of $454 million compared to $123 million at the end of FY22.
Regulatory ApprovalManagement plans to pursue accelerated approval for both DYNE-101 (in DM1) and DYNE-251 (DMD) programs.
Bears Say
Clinical Trial ResultsA dose-dependent effect was not clearly visible in most of the functional endpoints including Stride Velocity 95th Centile, timed rise from floor, and timed 10-meter walk/run test at the 6 month mark.
Management ChangesChanges to the management team, including the stepping down of key executives, are expected to weigh on the stock.
Safety ConcernsThe tradeoff of magnitude of increased dystrophin expression vs the potential safety risk now appears less favorable.
---
Ownership Overview
22.83% Insiders
18.96% Mutual Funds
0.43% Other Institutional Investors
46.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DYN FAQ
What was Dyne Therapeutics’s price range in the past 12 months?
Dyne Therapeutics lowest stock price was $6.40 and its highest was $47.45 in the past 12 months.
What is Dyne Therapeutics’s market cap?
Currently, no data Available
When is Dyne Therapeutics’s upcoming earnings report date?
Dyne Therapeutics’s upcoming earnings report date is Oct 31, 2024 which is in 18 days.
How were Dyne Therapeutics’s earnings last quarter?
Dyne Therapeutics released its earnings results on Aug 12, 2024. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.718 by $0.018.
Is Dyne Therapeutics overvalued?
According to Wall Street analysts Dyne Therapeutics’s price is currently Undervalued.
Does Dyne Therapeutics pay dividends?
Dyne Therapeutics does not currently pay dividends.
What is Dyne Therapeutics’s EPS estimate?
Dyne Therapeutics’s EPS estimate is -$0.71.
How many shares outstanding does Dyne Therapeutics have?
Dyne Therapeutics has 100,400,795 shares outstanding.
What happened to Dyne Therapeutics’s price movement after its last earnings report?
Dyne Therapeutics reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.718. Following the earnings report the stock price went up 1.323%.
Which hedge fund is a major shareholder of Dyne Therapeutics?
Among the largest hedge funds holding Dyne Therapeutics’s share is RA Capital Management. It holds Dyne Therapeutics’s shares valued at 213M.
---
Dyne Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.50 (55.93% Upside)
$52.50 (55.93% Upside)
Blogger Sentiment
Bullish
DYN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
301.78%
12-Months-Change
Fundamentals
Return on Equity
-52.46%
Trailing 12-Months
Asset Growth
228.49%
Trailing 12-Months
Company Description
Dyne Therapeutics
Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.
---
DYN Stock 12 Month Forecast
Average Price Target
$52.50
▲(55.93% Upside)
Technical Analysis
Scholar Rock Holding
―
Rocket Pharmaceuticals
―
Wave Life Sciences
―
Fulcrum Therapeutics
―
Best Analysts Covering DYN
1 Year
1 Year Success Rate
8/9 ratings generated profit
1 Year Average Return
+72.83%
reiterated a buy rating last month
Copying Francois Brisebois's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +72.83% per trade.
---